Eli Lilly (LLY) Other Accumulated Expenses (2009 - 2026)

Eli Lilly (LLY) has reported Other Accumulated Expenses for 18 consecutive years, with $8.7 billion the latest figure, recorded in Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $8.7 billion, up 130.75% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.7 billion (up 130.75% YoY), and the FY2025 annual result was $8.5 billion, up 32.2% from the prior year.
• Other Accumulated Expenses was $8.7 billion for Q1 2026 at Eli Lilly, up from $8.5 billion in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $8.7 billion in Q1 2026 and troughed at $2.0 billion in Q3 2022.
• Average Other Accumulated Expenses over 5 years is $4.2 billion, with a median of $3.8 billion recorded in 2025.
• Year-over-year, Other Accumulated Expenses dropped 23.67% in 2022 and surged 130.75% in 2026.
• Over 5 years, Other Accumulated Expenses stood at $2.8 billion in 2022, then grew by 15.32% to $3.3 billion in 2023, then surged by 94.95% to $6.4 billion in 2024, then soared by 32.2% to $8.5 billion in 2025, then gained by 2.86% to $8.7 billion in 2026.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $8.7 billion in Q1 2026, $8.5 billion in Q4 2025, and $5.2 billion in Q3 2025.